These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 20210685)

  • 1. Pharmacotherapy of systemic sclerosis.
    Postlethwaite AE; Harris LJ; Raza SH; Kodura S; Akhigbe T
    Expert Opin Pharmacother; 2010 Apr; 11(5):789-806. PubMed ID: 20210685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
    Hasegawa M; Takehara K
    Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Trial Design Issues in Systemic Sclerosis: an Update.
    Gordon JK; Domsic RT
    Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in biological and targeted therapies for systemic sclerosis.
    Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
    Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis.
    Del Papa N; Zaccara E
    Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):756-69. PubMed ID: 27107511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs and therapeutics for systemic sclerosis.
    Lee JJ; Pope JE
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic sclerosis: an update.
    Varga J
    Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis.
    Farina N; Campochiaro C; Lescoat A; Benanti G; De Luca G; Khanna D; Dagna L; Matucci-Cerinic M
    Expert Rev Clin Immunol; 2023; 19(9):1131-1142. PubMed ID: 37366065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies.
    Asano Y; Varga J
    Semin Cell Dev Biol; 2020 May; 101():146-160. PubMed ID: 31859147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.
    McMahan ZH; Volkmann ER
    Expert Opin Pharmacother; 2020 Nov; 21(16):2041-2056. PubMed ID: 32674612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis.
    Ntelis K; Solomou EE; Sakkas L; Liossis SN; Daoussis D
    Semin Arthritis Rheum; 2017 Dec; 47(3):409-417. PubMed ID: 28602360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
    Khanna D; Brown KK; Clements PJ; Elashoff R; Furst DE; Goldin J; Seibold JR; Silver RM; Tashkin DP; Wells AU
    Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S55-62. PubMed ID: 20576216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New pathogenic and therapeutic concepts in systemic sclerosis.
    Hügle T; Huigens CA; van Laar JM
    Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.
    Luo Y; Wang Y; Shu Y; Lu Q; Xiao R
    Int J Biochem Cell Biol; 2015 Oct; 67():92-100. PubMed ID: 26043891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology of systemic sclerosis: current understanding and new insights.
    Cutolo M; Soldano S; Smith V
    Expert Rev Clin Immunol; 2019 Jul; 15(7):753-764. PubMed ID: 31046487
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel investigational agents for the treatment of scleroderma.
    McMahan ZH; Wigley FM
    Expert Opin Investig Drugs; 2014 Feb; 23(2):183-98. PubMed ID: 24261610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
    Lescoat A; Varga J; Matucci-Cerinic M; Khanna D
    Expert Opin Investig Drugs; 2021 Jun; 30(6):635-652. PubMed ID: 33909517
    [No Abstract]   [Full Text] [Related]  

  • 18. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.
    Merkel PA; Clements PJ; Reveille JD; Suarez-Almazor ME; Valentini G; Furst DE;
    J Rheumatol; 2003 Jul; 30(7):1630-47. PubMed ID: 12858472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contemporary management of systemic sclerosis.
    Eldoma M; Pope J
    Expert Rev Clin Immunol; 2018 Jul; 14(7):573-582. PubMed ID: 29874475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis.
    Stenström M; Nyhlén HC; Törngren M; Liberg D; Sparre B; Tuvesson H; Eriksson H; Leanderson T
    J Dermatol Sci; 2016 Jul; 83(1):52-9. PubMed ID: 27156795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.